Which Peptides Are Legal to Compound in 2026? Full FDA Status Guide

Which Peptides Are Legal to Compound in 2026? Full FDA Status Guide

Published May 11, 2026 • Newtropin Editorial Team • Last Updated: May 2026

Navigating the regulatory landscape for legal peptides in 2026 for compounding can be confusing — but it does not have to be. With the FDA’s major April 15, 2026 update to the 503A bulk drug substances document, the status of dozens of popular peptides and therapeutic compounds has shifted. Some are moving toward greater access; others remain under evaluation. This guide is your definitive reference — a complete, regularly updated table of every relevant peptide and its current FDA category status, what each category means for patient access, and what is coming next. Bookmark this page and check back monthly for the latest updates.

Last Updated: May 2026 • Based on the FDA 503A Bulk Drug Substances document updated April 15, 2026. This page is updated monthly to reflect the latest regulatory changes.

Understanding the Three Categories

The FDA organizes nominated bulk drug substances into three categories that determine whether compounding pharmacies can legally use them. Understanding these categories is the key to knowing whether your peptide is accessible through legitimate pharmacy channels:

Category
Name
What It Means for Patients




1
Under Evaluation
Generally available for compounding while evaluation is ongoing. Your pharmacy can likely prepare these with a valid prescription.


2
Significant Safety Concerns
Compounding is restricted or effectively blocked. Pharmacies generally cannot prepare these substances.


3
Nominated Without Adequate Support
Insufficient data submitted. Not approved for compounding until additional evidence is provided.

Peptides Being Removed from Category 2 → PCAC Review

These peptides were previously in Category 2 (safety concerns) and are now being removed and scheduled for PCAC (Pharmacy Compounding Advisory Committee) review. This is a major positive development that signals the FDA is reconsidering these peptides for legal compounding status:

Peptide
Forms
PCAC Meeting Date
Primary Use




BPC-157
Acetate & Free Base
July 23, 2026
Gut healing, tissue repair, anti-inflammatory


KPV
Acetate & Free Base
July 23, 2026
Anti-inflammatory, gut immune support


MOTs-C
Acetate & Free Base
July 23, 2026
Metabolic optimization, exercise mimetic


TB-500 (LKKTETQ)
Acetate & Free Base
July 23, 2026
Tissue regeneration, wound healing


Emideltide (DSIP)
Acetate & Free Base
July 24, 2026
Sleep regulation, stress reduction


Epitalon
Acetate & Free Base
July 24, 2026
Anti-aging, telomere lengthening


Semax
Acetate & Free Base
July 24, 2026
Cognitive enhancement, neuroprotection


GHK-Cu (injectable)
Injectable route
Before Feb 2027
Anti-aging, skin rejuvenation, wound healing


Cathelicidin LL-37
—
Before Feb 2027
Antimicrobial, immune defense


Dihexa Acetate
—
Before Feb 2027
Cognitive enhancement, neuroregeneration


PEG-MGF
—
Before Feb 2027
Muscle growth, recovery


Melanotan II
—
Before Feb 2027
Skin tanning, sexual function

Removals from Category 1

GHK-Cu (except for injectable routes) is being removed from Category 1, with PCAC consultation scheduled before February 2027. This means that topical and other non-injectable forms of GHK-Cu are transitioning out of the general evaluation category and into the PCAC review pipeline for a definitive determination on compounding status. For more on GHK-Cu’s unique dual-track regulatory situation, read our dedicated GHK-Cu FDA status guide.

Category 1 Peptides: Currently Under Evaluation

These substances remain in Category 1 (Under Evaluation) and are generally available through compounding pharmacies while the FDA continues its assessment. This list includes many of the most popular peptides in clinical use today:

Note: This table covers the substances most relevant to the newtropin.com audience; FDA's full 503A category list contains many more, and the FDA peptide status tracker follows changes. For growth hormone-related peptides, see our CJC-1295 + Ipamorelin guide.

What Each Category Means for Your Access

Category 1 — Under Evaluation

If the peptide you use is in Category 1, access is generally maintained through compounding pharmacies with a valid prescription. However, “under evaluation” means the FDA has not made a final determination. Patients should work with their prescriber and pharmacy to ensure continuous access and have contingency plans in case a substance’s category changes during the review process.

Category 2 → PCAC Review (Transitioning)

Peptides being removed from Category 2 are in a transitional state. They are no longer classified as safety concerns, but they have not yet been officially approved for 503A compounding. Access during this transition depends on your state’s regulations and your pharmacy’s policies. The PCAC meetings in July 2026 and before February 2027 will produce recommendations that guide the FDA’s final decisions. This is the most dynamic category right now — and the one generating the most patient interest.

Category 3 — Insufficient Support

If a substance is in Category 3, it generally cannot be compounded. Additional data must be submitted to the FDA to advance it to Category 1 or the PCAC review stage. Patient advocacy groups and industry stakeholders can help by submitting supporting evidence for substances in this category.

Key Dates to Watch

Date
Event
Peptides Affected




July 23, 2026
PCAC Meeting Day 1
BPC-157, KPV, MOTs-C, TB-500


July 24, 2026
PCAC Meeting Day 2
Emideltide (DSIP), Epitalon, Semax


Before Feb 2027
Additional PCAC Session(s)
GHK-Cu, LL-37, Dihexa, PEG-MGF, Melanotan II

How to Stay Updated

The FDA peptide regulatory landscape is dynamic. New PCAC meetings, rule changes, and category shifts can occur throughout the year. To stay current:

• Bookmark this page — we update it monthly with the latest category statuses and any new FDA announcements
• Subscribe to Newtropin updates — get regulatory news and analysis delivered to your inbox before anyone else
• Follow the FDA’s 503A document — the official source for category assignments at fda.gov
• Talk to your prescriber regularly — they can provide guidance on how changes affect your specific protocol
• Visit our peptide guides — explore our BPC-157 guide, our peptide weight loss guide, and other resources for in-depth information on specific peptides

Conclusion: Your Complete Peptide Status Reference

This page is designed to be the single most useful resource for understanding which peptides are legal to compound in 2026 and beyond. As the FDA processes PCAC recommendations from the July 2026 meetings and the early 2027 sessions, we will update the tables above to reflect every change. Stay ahead of the curve by bookmarking this page, subscribing to newtropin.com updates, and sharing this resource with your healthcare provider and fellow peptide patients.

📌 Subscribe for Monthly Updates — Never miss a category change. Get the latest FDA peptide status updates delivered to your inbox at newtropin.com.

Disclaimer: This content is for informational purposes only and does not constitute legal or medical advice. Regulatory status may change. Always consult a qualified healthcare provider and check current FDA guidance before starting any peptide therapy.